| |
|
|
X4 Pharmaceuticals Inc (NASDAQ: XFOR) |
|
|
|
|
X4 Pharmaceuticals Inc's Pre-Tax Profit Margin by quarter
Trends, Rankings, Statistics
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| XFOR Pre-Tax Profit Margin |
(Mar 31 2025)
Q1 |
(Dec 31 2024)
Q4 |
(Sep 30 2024)
Q3 |
(Jun 30 2024)
Q2 |
(Mar 31 2024)
Q1 |
| Y / Y Revenue Change |
- |
- |
- |
- |
- |
| Seq. Revenue Change |
1908.86 % |
156.07 % |
-0.53 % |
- |
- |
| Revenue In Millions |
$28.81 |
$1.43 |
$0.56 |
$0.56 |
$0.00 |
| Pre-Tax Profit Margin |
1.1 % |
-2758.93 % |
-6550.18 % |
- |
- |
| Pre-Tax Profit Margin Total
Ranking |
# 2201 |
# |
# |
# 6 |
# |
| Pre-Tax Income In Millions |
$0.32 |
$-39.56 |
$-36.68 |
$90.85 |
$-51.75 |
| Y / Y Pre-Tax Income Change |
- |
- |
- |
- |
- |
| Seq. Pre-Tax Income Change |
- |
- |
- |
- |
- |
| Commenting First Quarter 2025 Pre-Tax Profit Margin |
X4 Pharmaceuticals Inc achieved Pre-Tax Income of $0 millions compare to Pre-Tax Loss of $-39.56 millions recorded in the previous quarter. Revenue increased by 1908.86 % Company accomplished below the average Pre-Tax Profit Margin with 1.1 %.
Observing first quarter 2025 results within Biotechnology & Pharmaceuticals industry 19 other companies have achieved higher Pre-Tax Profit Margin. While Pre-Tax Profit Margin overall ranking has deteriorated relative to the three months before, from to 2201.
|
| XFOR's Pre-Tax Profit Margin first quarter 2025 Company Ranking |
| Within: |
No. |
| Biotechnology & Pharmaceuticals Industry |
# 20 |
| Healthcare Sector |
# 178 |
| Overall |
# 2201 |
| Pre-Tax Profit Margin Statistics |
| High |
Average |
Low |
| 16136.94 % |
8069.02 % |
1.1 % |
| (Jun 30 2024) |
|
(Mar 31 2025) |
| Companies with similar Pre-Tax Profit Margin in the quarter ending Mar 31 2025, within Biotechnology & Pharmaceuticals Industry | Pre-Tax Profit Margin | Mar 31 2025 MRQ Pre-Tax Income | Mar 31 2025 MRQ Revenue | | Neurocrine Biosciences Inc | 2.57 % | $ 14.700 Millions | $ 572.600 Millions | | X4 Pharmaceuticals Inc | 1.10 % | $ 0.316 Millions | $ 28.807 Millions | | Biocryst Pharmaceuticals Inc | 0.52 % | $ 0.758 Millions | $ 145.534 Millions |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
